Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Gliosarcoma × Daclizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Gliosarcoma 1 Glioma 1 Glioblastoma 1

Interventions

Temozolomide 44 Radiotherapy 25 Radiation 13 O(6)-benzylguanine 7 Irinotecan 7 Chemotherapy, Adjuvant 7 Erlotinib Hydrochloride 6 Carmustine 6 motexafin gadolinium 5 Surgical Procedures, Operative 5 Imatinib Mesylate 5 sargramostim 4 Radiotherapy, Intensity-Modulated 4 Magnetic Resonance Spectroscopy 4 Hydroxyurea 4 Gene Expression Profiling 4 Radiotherapy, Conformal 3 Immunohistochemistry 3 Genetic Therapy 3 Filgrastim 3 Drug Therapy 3 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3 vandetanib 2 lonafarnib 2 cediranib 2 Specimen Handling 2 Sorafenib 2 Radiosurgery 2 Nivolumab 2 Mass Spectrometry 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00626015 2016-01-21

ZAP IT

Duke University

Phase 1 Completed

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡